Overview of Azithromycin Sanofi

Property	Description
Active ingredient	Azithromycin dihydrate
Form	Tablet, Oral Suspension, IV Solution, Eye Drops
Pharmacological class	Macrolide Antibiotic (Azalide subclass)
Common use	Combating bacterial infections
Origin	Semisynthetic

Azithromycin Sanofi: A Semisynthetic Antibiotic

Azithromycin Sanofi is a prescription-only antimicrobial agent belonging to the azalide subclass of macrolide antibiotics. The core active substance is Azithromycin dihydrate, a semisynthetic compound derived through the chemical modification of the natural macrolide Erythromycin. This single-ingredient product functions primarily as a protein synthesis inhibitor in susceptible bacteria, effectively disrupting their ability to grow and multiply. Azithromycin possesses a high volume of distribution, allowing it to achieve sustained concentrations in body tissues. This property contributes to its prolonged duration of action compared to older macrolides.

Dosage Forms and General Therapeutic Purpose

The fundamental purpose of Azithromycin is its broad-spectrum antimicrobial activity, which is designed to halt the proliferation of common bacterial infections throughout the body. Azithromycin offers versatility in its delivery, typically manufactured in multiple pharmaceutical presentations, including film-coated tablets for oral administration, a powder for oral suspension (often preferred for pediatric use), and specialized forms for intravenous and ophthalmic use. Azithromycin exhibits stability under acidic conditions and a long terminal half-life compared to other macrolides. This indicates that the medicine is well-absorbed and effective in aiding the patient's immune system to resolve infectious disease states over time. This efficacy is recognized in treating common respiratory or skin infections where susceptible organisms are involved.

Regulatory References

U.S. National Library of Medicine

What side effects are possible with Azithromycin Sanofi?

Possible Side Effects and Safety Information

Azithromycin, like all medications, is associated with a range of possible side effects and important safety warnings detailed in regulatory documents.

Common and Serious Adverse Reactions

The most Common adverse reactions are generally mild gastrointestinal disturbances, including diarrhea, nausea, abdominal pain, and vomiting (typically occurring in 3% to 18% of patients in clinical trials, depending on the reaction). Headache is also commonly reported.

Serious adverse reactions are rare but require immediate attention and include:

Cardiovascular Events: The drug can cause prolongation of the QT interval on an ECG, leading to potentially fatal heart rhythm abnormalities such as torsades de pointes and sudden cardiovascular death. This risk may be increased in the elderly and those with existing cardiac risk factors or uncorrected electrolyte imbalances.
Hepatotoxicity: Cases of severe and sometimes fatal liver injury have been reported, including hepatic necrosis and hepatic failure. The drug is contraindicated in patients with a history of cholestatic jaundice or liver dysfunction associated with its prior use.
Hypersensitivity and Skin Reactions: Serious, sometimes fatal, allergic reactions (e.g., anaphylaxis, angioedema) and severe dermatologic reactions (Stevens-Johnson Syndrome, DRESS) have been reported, sometimes recurring after initial symptomatic treatment due to the drug's long half-life.
Gastrointestinal: The development of Clostridioides difficile-Associated Diarrhea (CDAD) is a possibility, ranging from mild diarrhea to fatal colitis.
Population-Specific Risk: In neonates (up to 42 days old), there is a reported risk of Infantile Hypertrophic Pyloric Stenosis (IHPS).

Safety Restrictions and Monitoring

Azithromycin is contraindicated in patients with known hypersensitivity to any macrolide or ketolide antibiotic and in patients with prior azithromycin-associated liver dysfunction. Caution is warranted in patients with pre-existing QT prolongation or myasthenia gravis, as the drug may exacerbate muscle weakness. Regulatory documents advise immediate drug discontinuation if signs of serious cardiac or hepatic dysfunction or severe allergic reactions appear.

Overdose and Emergency Response

Overdose and when to seek help

Documented Overdose Presentations Overdosage with Azithromycin may present with an intensification of common gastrointestinal adverse reactions, including severe nausea, vomiting, diarrhea, and stomach discomfort. These manifestations are generally similar to those observed at normal doses but amplified due to exposure above recommended levels. The primary severe risk associated with overdosage is the potential for life-threatening cardiotoxicity.

Severe and Life-Threatening Outcomes Regulatory documents warn of prolonged QT interval and the associated risk of developing the potentially fatal arrhythmia known as Torsades de pointes. Cases of severe hepatic necrosis and liver failure, some resulting in death, have also been reported and are considered severe outcomes. Elderly patients and individuals with pre-existing cardiac disease are noted as potentially more susceptible to these arrhythmogenic effects.

Immediate Actions and Supportive Management In the event of suspected overdosage, general symptomatic and supportive measures are indicated as required by prescribing information, as no specific antidote is officially listed. The mandatory requirement is to seek immediate medical care if symptoms of cardiac irregularity occur, such as an irregular heartbeat, sudden dizziness, or fainting. Contacting a healthcare professional or emergency services immediately is required even if acute symptoms are limited to gastrointestinal distress.

Therapeutic Uses of Azithromycin Sanofi

What Azithromycin Sanofi Treats: Main Uses and Benefits

Azithromycin Sanofi is commonly used across therapeutic domains where short-term symptom management is appropriate, applied across domains where additional symptomatic support is needed due to heightened patient distress or functional strain. This antimicrobial agent is used to treat infections of the ears, lungs, sinuses, skin, throat, and reproductive organs.

Managing Acute Symptoms of Respiratory and Sinus Infections

This medication helps address symptom clusters that may become intense or disruptive within the respiratory system, including community-acquired pneumonia, sinusitis, and acute bacterial exacerbations of chronic bronchitis (COPD). It offers symptomatic relief that helps patients cope more steadily with difficult episodes, and may assist with managing symptoms that create noticeable physiological strain like severe coughing, chest congestion, and purulent discharge.

“It is commonly used across conditions presenting with acute episodes where short-term symptomatic assistance is needed.”

Addressing Localized Skin, Ear, and Throat Discomfort

Azithromycin is relevant in clinical settings marked by increased discomfort or tension in localized areas. It is applied in cases where symptoms related to physical discomfort cluster into patterns requiring supportive management for conditions like acute otitis media (ear infection), pharyngitis/tonsillitis (sore throat/swollen tonsils), and uncomplicated skin infections. It is relevant for easing the symptom load, such as acute localized pain, swelling, and fever, and may help patients cope more steadily with symptom fluctuations.

Supportive Therapy for Specific Urogenital and Systemic Conditions

This medicine is applied across domains where short-term symptomatic assistance is appropriate for conditions presenting with systemic or localized discomfort, including uncomplicated chlamydia, urethritis, and cervicitis, as well as other conditions like genital ulcer disease and certain systemic mycobacterial infections (e.g., MAC prophylaxis). It helps maintain a sense of stability when symptoms are more noticeable and is relevant for easing symptoms that create noticeable physiological strain, such as abnormal discharge and localized inflammation.

Quick Fact: Relief for Acute Pain and Fever Azithromycin is generally relevant when symptoms related to systemic imbalance, such as fever and localized pain in the ear or throat, are present due to a susceptible bacterial infection.

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Azithromycin Sanofi? (Eligibility Profile)

Eligibility for azithromycin is strictly defined by regulatory guidelines, focusing on absolute contraindications and conditions requiring specific caution. This section outlines the official criteria for use.

Contraindications and Absolute Restrictions

Classification	Who MUST NOT Use the Medicine
Hypersensitivity	Individuals with a known allergy to azithromycin, erythromycin, any macrolide, or any ketolide antibiotic are formally excluded.
Prior Hepatic Reaction	Patients with a history of cholestatic jaundice or hepatic dysfunction specifically associated with previous azithromycin use.

Populations Requiring Caution or Restricted Use

Population/Condition	Regulatory Requirement
Severe Hepatic Impairment	Not recommended due to the primary route of elimination via the liver.
Severe Renal Impairment	Caution is required (GFR < 10 mL/min) due to increased systemic exposure.
Cardiac Conditions	Special caution is needed for patients at risk of QT interval prolongation (e.g., existing arrhythmia or severe cardiac insufficiency).
Infants (< 6 months)	Safety and effectiveness are not established for most common indications.
Pregnancy/Lactation	Use only if clearly needed, as small amounts are excreted in breast milk and human studies are limited.

Summary

The official profile mandates absolute exclusion based on allergy or prior serious adverse reactions. Use is conditional, requiring careful medical assessment, for patients with compromised liver or kidney function, specific cardiac risks, and in infancy or during pregnancy and lactation.

What should I know about interactions with other medicines?

Official Regulatory Interaction Profile

The documented interaction profile for Azithromycin is defined by prohibitions and requirements for careful monitoring, based on pharmacokinetic and pharmacodynamic outcomes cited in regulatory documents.

Interaction Classification	Official Statement or Restriction
Contraindicated Combinations	Co-administration is formally prohibited with medicines known to prolong the QT interval, such as Pimozide and Cisapride, due to the documented risk of additive cardiac repolarization and Torsades de Pointes. Combination with Ergot Alkaloids (Ergotamine) is also prohibited due to the theoretical potential for acute ergotism.
Pharmacokinetic Alterations	Azithromycin acts as an inhibitor of the P-glycoprotein (P-gp) efflux transporter. This interaction may elevate the plasma concentrations of co-administered P-gp substrates, including Digoxin and Colchicine, necessitating clinical monitoring. Concomitant use with Nelfinavir is documented to increase Azithromycin's own systemic exposure.
Coagulation and Timing Rules	Official reports note that Azithromycin may potentiate the effect of Warfarin (oral anticoagulants), requiring close monitoring of coagulation metrics (INR). Furthermore, Aluminum- or Magnesium-Containing Antacids reduce the peak plasma concentration ( Cmax) of Azithromycin; therefore, regulatory documents require administration to be separated by a minimum of two hours.
Population-Specific Notes	Increased Azithromycin systemic exposure ( AUC) is officially documented in patients with severe renal impairment ( GFR < 10 mL/min) and in those with hepatic impairment.

This structured profile accurately defines the mandatory restrictions and monitoring protocols based on the observed and verified effects of co-administration as cited in official health authority documents.

Mechanism of Action

How Azithromycin Sanofi Works

The action of Azithromycin Sanofi is defined by its highly specific molecular targeting within susceptible bacteria, which halts proliferation and facilitates the clearance of organisms by the host's immune system.

Blocking the Bacterial 50S Ribosomal Exit Tunnel

Azithromycin's primary mechanism is the physical blockade of the 50S ribosomal subunit within bacterial cells. It binds reversibly to the 23S rRNA, specifically obstructing the exit tunnel necessary for nascent protein chains to emerge. This targeted molecular interaction immediately inhibits the protein synthesis pathway . The subsequent failure to produce essential proteins results in the state of bacteriostasis, which is the arrest of bacterial multiplication.

Arresting Pathogen Growth and Facilitating Host Clearance

The molecular inhibition of protein synthesis initiates a mechanistic cascade: molecular blockade ightarrow cessation of bacterial growth ightarrow decline in active pathogen population. By preventing the proliferation of the bacterial population, the mechanism facilitates the subsequent action of the host's immune system to clear the remaining, non-proliferating organisms.

Understanding Mechanistic Constraints

The drug's effectiveness is constrained by specific microbial defense mechanisms, including the expression of efflux pumps that actively expel Azithromycin from the cell and the production of methyltransferase enzymes that alter the ribosomal binding site. These bacterial defense pathways limit the drug's ability to engage its target, thereby preventing the physiological outcome of growth inhibition.

Dosage and Administration Information

How Azithromycin Sanofi is Used: Official Administration Guidelines

Azithromycin Sanofi is administered through several routes, including oral (tablets or suspension), intravenous (IV) infusion, and topical (ophthalmic) application. The medicine is typically taken once daily, with regimens designed for short courses, usually spanning three to five days.

Standard Dosing and Administration

Official dosing protocols specify the amount of azithromycin per day. Adult courses commonly involve a total dose of 1,500 mg administered as 500 mg once daily for three days, or a 5-day regimen starting with 500 mg on Day 1, followed by 250 mg on Days 2 through 5. For certain conditions, a single oral dose of 1 g or 2 g is prescribed.

Administration Detail	Official Requirement	Administration Context
Oral Tablet/Suspension	May be taken with or without food.	Immediate-release forms allow flexible meal timing.
Extended-Release	Must be taken on an empty stomach.	Required for the 2 g single-dose formulation (e.g., at least 1 hour before a meal).
IV Solution	Requires reconstitution and dilution, then must be given as a slow infusion over 60 minutes or longer.	Forbidden as a bolus or intramuscular injection.
Pediatric Use	Dosing is calculated based on body weight (mg/kg).	Different dosage forms (suspensions) are used for children under 45 kg.

Use Protocol

If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped to prevent taking a double dose. For patients with mild-to-moderate renal or hepatic impairment, no dose adjustment is generally required. The administration sequence, whether oral or intravenous, is strictly defined by the total course duration and the required once-daily schedule.

Recent Clinical Evidence

Azithromycin Sanofi: Overview of Studies

This section summarizes the structure of clinical research conducted for Azithromycin Sanofi, detailing the types of studies performed, the populations examined, and findings reported in scientific literature. This information is purely descriptive.

Evidence for Use in Respiratory and Ear Infections

Clinical trials and reviews have explored Azithromycin for conditions involving periods of heightened symptoms in the airways, such as Community-Acquired Pneumonia (CAP) and Acute Bacterial Exacerbations of Chronic Bronchitis (COPD). Studies monitored outcomes including measurements of clinical response, the time patients took to achieve clinical status, and long-term systemic measures like mortality over intervals up to 180 days. Findings often reported that clinical measurements in Azithromycin groups were similar to patterns reported for comparator antibiotic regimens.

For Acute Otitis Media (AOM), randomized controlled trials examined outcomes related to clinical failure and bacteriological eradication levels. Research highlights concerns that bacteriological outcomes against specific common ear pathogens may be less consistent.

Long-Term Evidence and Uncertainty

Research has primarily focused on the short-term clinical outcome after the completion of the 3-day or 5-day treatment course. For many acute infections, follow-up durations were limited. While some studies have monitored long-term outcomes, data for long-term outcomes remain insufficient for many approved uses.

Research examined Azithromycin in different age groups, primarily pediatric patients (aged 6 months and older) and older adults. Data for certain groups remain insufficient, particularly infants younger than 6 months of age for several indications. A key finding consistently reported across various studies is the concern over increasing macrolide resistance.

Key Studies & References

Macrolides in the treatment of group A streptococcal pharyngitis and scarlet fever: A Systematic Review and Meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Azithromycin Sanofi (FAQ)

Q: Can I take azithromycin with ibuprofen (a common over-the-counter painkiller)?

Official clinical studies have not identified a specific drug interaction between azithromycin and ibuprofen. The regulatory information does not list this combination as one that is prohibited. The official label suggests that all co-administered products should be reviewed by a healthcare professional to manage potential unknown risks.

Q: Does azithromycin interact with birth control pills or devices?

According to official product information and clinical guidance, azithromycin does not interfere with the effectiveness of hormonal birth control. This includes combination pills, progesterone-only pills, and emergency contraception. Open communication with a healthcare provider regarding all current medications is noted in official guidance.

Q: Are fatigue or dizziness common side effects of azithromycin?

Official reports from clinical trials and post-marketing surveillance indicate that feeling dizzy or fatigued (tired) has been reported as a common or uncommon side effect of the medicine. These effects are noted alongside other effects such as headache. Official guidance states that any experienced side effects should be noted and discussed with a healthcare professional.

Q: Does azithromycin affect my ability to drive or operate machinery?

The official regulatory information states that there are no specific data detailing the effect of azithromycin on a patient's ability to drive or use machinery. However, due to the possible occurrence of undesirable effects like dizziness or convulsions, patients may wish to consider these possibilities before performing tasks requiring concentration.

Q: Is it safe to take azithromycin with herbal remedies or supplements?

Regulatory information indicates that there is not sufficient data to definitively state that all herbal remedies or complementary supplements are safe to use with azithromycin. The official label indicates that a healthcare professional should be informed about all current supplements to manage potential interactions.

Q: Can I use azithromycin for non-infectious conditions like an inflamed joint?

Azithromycin is an antibacterial drug, meaning its indicated purpose is the treatment of mild to moderate infections caused by susceptible bacteria. Official regulatory documents clearly indicate that this medicine is not effective against viral illnesses, such as the common cold, nor is it approved for non-infectious inflammatory conditions.

Q: Will azithromycin make my skin more sensitive to the sun?

Official safety warnings note that photosensitivity has been reported as a possible effect. Photosensitivity means an increased sensitivity or reaction to sunlight. Regulatory documents describe the importance of reducing excessive exposure to sunlight and artificial UV light due to this potential for photosensitivity.

Q: Is it safe to drink alcohol while I am on azithromycin?

Official regulatory guidance does not list a specific adverse interaction between azithromycin and alcohol. However, since the medicine is metabolized by the liver, and alcohol can worsen common gastrointestinal side effects like nausea or diarrhea, awareness of these potential effects is described as warranted during treatment.

Q: Are there any contraindications for azithromycin use in immunocompromised patients?

Official regulatory documentation states that azithromycin is not indicated for use in specific, severe contexts. This includes patients with bacteremia (bacteria in the bloodstream) or those who are hospitalized, debilitated, or considered immunocompromised for the treatment of pneumonia.

Q: Can I take azithromycin with over-the-counter cold and flu medicine?

Official clinical interaction studies typically do not test azithromycin against general over-the-counter cold and flu preparations. Regulatory sources note that some cold and flu medicines contain ingredients with cardiovascular effects, suggesting specific patient groups may require heightened awareness regarding use.

Q: What is the maximum duration I can be on azithromycin treatment?

The duration of treatment is typically decided by the prescribing doctor based on the infection, but official regulatory documents describe acute treatment courses typically lasting 1 to 5 days. The medicine is also sometimes described as being used in long-term regimens for the prevention of certain chronic chest infections.

Q: Is there a difference between brand-name (e.g., Sanofi) and generic azithromycin?

According to government health authorities, generic versions of azithromycin contain the exact same active ingredient as brand-name versions like Azithromycin Sanofi. Generic drugs must demonstrate that they work in the same way and have the same risks and benefits as the brand-name medicine before they are approved for use.

Q: What is the 'Z-Pak' and is it different from the standard azithromycin course?

Z-Pak is a common trade name associated with the original brand-name medication whose active ingredient is azithromycin. The term essentially refers to the active ingredient packaged in a specific, pre-determined dosage regimen over a short period. This regimen is detailed in official documents.

How should Azithromycin Sanofi be stored and disposed of?

How to Store and Dispose of Azithromycin

The official storage conditions for azithromycin vary by formulation, and all products must be kept out of the reach of children.

Storage Requirements

Formulation	Required Storage Condition	Stability/Shelf-Life Constraint
Tablets	Controlled Room Temperature (20 C to 25 C)	Store in a tightly closed container
Oral Suspension (Liquid)	5 C to 30 C. Do Not Freeze.	Stable for only 10 days after mixing
IV Solution (Diluted)	5 C (Refrigeration) or le 30 C	Stable for up to 7 days (refrigerated) or 24 hours (room temp)

Disposal

Regulatory labeling requires that any azithromycin oral suspension remaining after the full course of therapy MUST be discarded. Unused or expired tablets must be safely thrown away according to local regulations, utilizing drug take-back programs or general household waste disposal instructions.

Azithromycin Sanofi